[go: up one dir, main page]

CR11579A - Derivados de oxadiazol activos sobre fosfato de esfingosina-1 - Google Patents

Derivados de oxadiazol activos sobre fosfato de esfingosina-1

Info

Publication number
CR11579A
CR11579A CR11579A CR11579A CR11579A CR 11579 A CR11579 A CR 11579A CR 11579 A CR11579 A CR 11579A CR 11579 A CR11579 A CR 11579A CR 11579 A CR11579 A CR 11579A
Authority
CR
Costa Rica
Prior art keywords
active
sphingosine
phosphate
oxadiazol derivatives
oxadiazol
Prior art date
Application number
CR11579A
Other languages
English (en)
Inventor
Emmanuel Hubert Demont
Jag Paul Heer
Thomas Daniel Heightman
David Nigel Hurst
Christopher Norbert Johnson
John Skidmore
Ian David Wall
Jason Witherington
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0725120A external-priority patent/GB0725120D0/en
Priority claimed from GB0821918A external-priority patent/GB0821918D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR11579A publication Critical patent/CR11579A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente solicitud describe compuestos a base de oxadiazol de la formula (I), activos sobre 1-fosfato esfingosina (S1P) en particular utiles para tratar lupus eritematoso; A es fenilo o un anillo de heteroarilo de 5 o 6 miembros; R1 es de hasta dos sustituyentes independientemente seleccionados de halogeno
CR11579A 2007-12-21 2010-07-21 Derivados de oxadiazol activos sobre fosfato de esfingosina-1 CR11579A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0725120A GB0725120D0 (en) 2007-12-21 2007-12-21 Compounds
GB0821918A GB0821918D0 (en) 2008-12-01 2008-12-01 Compounds

Publications (1)

Publication Number Publication Date
CR11579A true CR11579A (es) 2010-09-03

Family

ID=40342566

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11579A CR11579A (es) 2007-12-21 2010-07-21 Derivados de oxadiazol activos sobre fosfato de esfingosina-1

Country Status (29)

Country Link
US (2) US8222245B2 (es)
EP (1) EP2222669B1 (es)
JP (1) JP2011506569A (es)
KR (1) KR20100108566A (es)
CN (1) CN101945863B (es)
AR (1) AR069916A1 (es)
AU (1) AU2008339988B2 (es)
BR (1) BRPI0820131A2 (es)
CA (1) CA2710130A1 (es)
CO (1) CO6290646A2 (es)
CR (1) CR11579A (es)
DK (1) DK2222669T3 (es)
DO (1) DOP2010000194A (es)
EA (1) EA017691B1 (es)
ES (1) ES2434730T3 (es)
HK (1) HK1142062A1 (es)
HR (1) HRP20130957T1 (es)
IL (1) IL206235A0 (es)
MA (1) MA31924B1 (es)
NZ (1) NZ585996A (es)
PE (1) PE20091339A1 (es)
PL (1) PL2222669T3 (es)
PT (1) PT2222669E (es)
RS (1) RS53038B (es)
SI (1) SI2222669T1 (es)
TW (1) TWI415847B (es)
UY (1) UY31570A1 (es)
WO (1) WO2009080725A1 (es)
ZA (1) ZA201003963B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
GB0725102D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
AU2009331990B2 (en) 2008-12-22 2016-04-14 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011028927A1 (en) * 2009-09-04 2011-03-10 Allergan, Inc. Selective sphingosine-1-phosphate receptor antagonists
ES2785475T3 (es) 2011-05-10 2020-10-07 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores de canales iónicos
CN102250035A (zh) * 2011-06-10 2011-11-23 北京富卡生物技术有限公司 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (es) 2011-07-01 2018-04-28
RU2543485C2 (ru) * 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
CN104844535A (zh) * 2014-02-13 2015-08-19 吉利德科学公司 用于制备稠合杂环离子通道调节剂的方法
UY36274A (es) 2014-08-20 2016-02-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
EP3227263B1 (en) 2014-12-01 2019-04-10 Idorsia Pharmaceuticals Ltd Cxcr7 receptor modulators
EP4291183A4 (en) * 2021-02-10 2025-01-08 Icahn School Med Mount Sinai OXADIAZOLYL DIHYDROPYRANO[2,3-B] PYRIDINE INHIBITORS OF HIPK2 FOR THE TREATMENT OF RENAL FIBROSIS
WO2023081328A1 (en) * 2021-11-04 2023-05-11 Valo Health, Inc. Histone deacetylase 6 inhibitor compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
MXPA03004243A (es) 2000-11-14 2004-03-16 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina utiles como moduladores de receptores de dopamina d3 (agentes antipsicoticos).
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
AU2004249664A1 (en) * 2003-05-19 2004-12-29 Irm Llc Immunosuppressant compounds and compositions
CN1859908A (zh) * 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
WO2005058848A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
GB0414795D0 (en) 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
US7659294B2 (en) 2004-10-22 2010-02-09 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
ES2378776T3 (es) 2004-12-13 2012-04-17 Ono Pharmaceutical Co., Ltd. Derivado de ácido aminocarboxílico y uso medicinal del mismo
PT1863787E (pt) * 2005-03-23 2011-07-29 Actelion Pharmaceuticals Ltd Derivados de benzo(c)tiofenos hidrogenados como imunomoduladores
PT1863474E (pt) 2005-03-23 2009-01-20 Actelion Pharmaceuticals Ltd Novos derivados de tiofeno como agonistas dos receptores 1 de esfingosina-1-fosfato
DE602006015297D1 (de) 2005-04-22 2010-08-19 Daiichi Sankyo Co Ltd 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva
KR20080014009A (ko) 2005-06-08 2008-02-13 노파르티스 아게 폴리시클릭 옥사디아졸 또는 이속사졸, 및 이들의 ｓ１ｐ수용체 리간드로서의 용도
EP1917240A1 (en) 2005-08-23 2008-05-07 Irm Llc Immunosuppressant compounds and compositions
JP2009517351A (ja) 2005-11-24 2009-04-30 グラクソ グループ リミテッド 化学物質
TWI382984B (zh) * 2006-04-03 2013-01-21 Astellas Pharma Inc 雜環化合物
WO2008064337A2 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
UY31570A1 (es) 2009-05-29
US20100174065A1 (en) 2010-07-08
HK1142062A1 (en) 2010-11-26
US8222245B2 (en) 2012-07-17
PE20091339A1 (es) 2009-09-26
TWI415847B (zh) 2013-11-21
BRPI0820131A2 (pt) 2015-05-12
CA2710130A1 (en) 2009-07-02
MA31924B1 (fr) 2010-12-01
PL2222669T3 (pl) 2014-01-31
EP2222669A1 (en) 2010-09-01
AU2008339988A1 (en) 2009-07-02
EA017691B1 (ru) 2013-02-28
CN101945863A (zh) 2011-01-12
EP2222669B1 (en) 2013-08-21
HRP20130957T1 (hr) 2013-11-08
KR20100108566A (ko) 2010-10-07
WO2009080725A1 (en) 2009-07-02
JP2011506569A (ja) 2011-03-03
ZA201003963B (en) 2011-11-30
CO6290646A2 (es) 2011-06-20
EA201070782A1 (ru) 2010-12-30
TW200940531A (en) 2009-10-01
CN101945863B (zh) 2013-07-03
RS53038B (en) 2014-04-30
PT2222669E (pt) 2013-10-28
SI2222669T1 (sl) 2013-10-30
DOP2010000194A (es) 2010-08-15
US20100273771A1 (en) 2010-10-28
DK2222669T3 (da) 2013-10-28
AR069916A1 (es) 2010-03-03
AU2008339988B2 (en) 2013-09-26
ES2434730T3 (es) 2013-12-17
NZ585996A (en) 2012-06-29
IL206235A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
CR11579A (es) Derivados de oxadiazol activos sobre fosfato de esfingosina-1
EA201170096A1 (ru) Замещенные производные пиримидона
CA2671233A1 (en) Soil treating agent or seed treating agent comprising quinoline compounds or salts thereof as active ingredient, or method for preventing plant diseases by using the same
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
MX2015003771A (es) Formulacion farmaceutica que contiene compuestos de tienotriazolodiazepina.
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
BR112013000273A8 (pt) derivados de imidazopiridina, processo para a preparação dos mesmos e uso terapêutico dos mesmos
AR065337A1 (es) Proceso para la sintesis de compuestos de 2- aminotiazol como inhibidores de quinasa, forma polimorfica
UY30323A1 (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
CO6290688A2 (es) Derivados de oxadiazol activos en 1-fosfato de esfingosina
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
BR112012001031A8 (pt) Compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
SG165361A1 (en) Antituberculous composition comprising oxazole compounds
PE20080038A1 (es) Derivados de tiazolidinadiona como inhibidores de la pi3 quinasa
ECSP088805A (es) 2-(piridin-2-il)-pirimidinas como fungicidas
BR112012005902A2 (pt) formulação de catalisador de quelato de ti, uso da formulação de catalisador de quelato de ti ou de um composto, composição, processo para a polimeração de compostos, catalisador de quelato de ti, uso da composição polimerizável, e, substrato revestido
AR069781A1 (es) Compuestos de n-(2,3-dihidro-inden-2-il) propanosulfonamida, composicion farmaceutica que los comprenden y su uso para el tratamiento de la ezquizofrenia.
CY1113251T1 (el) Παραγωγα σουλφονυλ-κινολινης
RS53965B1 (en) ACILBENZENA DERIVATIVES
BR112015007719A2 (pt) compostos do tipo pirona e herbicidas compreendendo os mesmos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)